Related references
Note: Only part of the references are listed.Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients
Y. H. Park et al.
BRITISH JOURNAL OF CANCER (2009)
Bevacizumab and Paclitaxel for Breast Cancer Patients with Central Nervous System Metastases: A Case Series
Sana Intidhar Labidi et al.
CLINICAL BREAST CANCER (2009)
Vorinostat Inhibits Brain Metastatic Colonization in a Model of Triple-Negative Breast Cancer and Induces DNA Double-Strand Breaks
Diane Palmieri et al.
CLINICAL CANCER RESEARCH (2009)
Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
Nancy U. Lin et al.
CLINICAL CANCER RESEARCH (2009)
Safety of Bevacizumab in Patients With Non-Small-Cell Lung Cancer and Brain Metastases
Mark A. Socinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Central Nervous System Metastases
Brian Leyland-Jones
JOURNAL OF CLINICAL ONCOLOGY (2009)
Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts
Andrew Baschnagel et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 trial
B. C. Pestalozzi et al.
ANNALS OF ONCOLOGY (2008)
High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer
O. Mir et al.
ANNALS OF ONCOLOGY (2008)
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
David Cameron et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Phase 2 Trial of Temozolomide Using Protracted Low-dose and Whole-brain Radiotherapy for Nonsmall Cell Lung Cancer and Breast Cancer Patients With Brain Metastases
Raffaele Addeo et al.
CANCER (2008)
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer
Nancy U. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas
A. Tosoni et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain
Brunilde Gril et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Characteristics of breast cancer patients with central nervous system metastases: A single-center experience
Hakan Harputluoglu et al.
JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION (2008)
A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases
Fabio M. Iwamoto et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Brain metastases in breast cancer: prognostic factors and management
Sung Sook Lee et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis
Kadri Altundag et al.
CANCER (2007)
Capecitabine therapy of central nervous system metastases from breast cancer
Meltem Ekenel et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Breast cancer leptomeningeal metastasis - the role of multimodality treatment
Halina Rudnicka et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
A phase I/II trial of topotecan and radiation therapy for brain metastases in patients with solid tumors
Jan-Peter Hedde et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Chemotherapy delivery issues in central nervous system malignancy: A reality check
Leslie L. Muldoon et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors
John R. Kouvaris et al.
ONKOLOGIE (2007)
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier
Hans-Joachim Stemmler et al.
ANTI-CANCER DRUGS (2007)
Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer
Zsolt Gabos et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma:: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
A. A. Brandes et al.
BRITISH JOURNAL OF CANCER (2006)
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma
Edgardo Rivera et al.
CANCER (2006)
Primary breast cancer phenotypes associated with propensity for central nervous system metastases
Yee-Lu Tham et al.
CANCER (2006)
Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients
Nikos Xenidis et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Vinorelbine combined with a protracted course of temozolomide for recurrent brain Metastases: a phase I trial
A. M. Omuro et al.
JOURNAL OF NEURO-ONCOLOGY (2006)
Systemic high-dose intravenous methotrexate for central nervous system metastases
AB Lassman et al.
JOURNAL OF NEURO-ONCOLOGY (2006)
Temozolomide in metastatic breast cancer (MBC): A phase II trial of the National Cancer Institute of Canada-Clinical Trials Group (NCIC-CTG)
ME Trudeau et al.
ANNALS OF ONCOLOGY (2006)
Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer
H. J. Stemmler et al.
BREAST (2006)
Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab
T Yau et al.
ACTA ONCOLOGICA (2006)
Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status
John Souglakos et al.
BREAST CANCER RESEARCH (2006)
Breast cancer metastasis to the central nervous system
RJ Weil et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy
M Ryberg et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study
C Christodoulou et al.
JOURNAL OF NEURO-ONCOLOGY (2005)
Phase I/II trial of simultaneous whole-brain irradiation and dose-escalating topotecan for brain metastases
M Kocher et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2005)
Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: A phase II randomized trial
E Verger et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment
E Shmueli et al.
EUROPEAN JOURNAL OF CANCER (2004)
Brain Metastases from breast cancer: Identification of a high-risk group
AJ Evans et al.
CLINICAL ONCOLOGY (2004)
The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study
W Boogerd et al.
EUROPEAN JOURNAL OF CANCER (2004)
Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment
AM Gonzalez-Angulo et al.
CANCER (2004)
Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study
M Donadio et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2003)
Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival
KD Miller et al.
ANNALS OF ONCOLOGY (2003)
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma
JC Bendell et al.
CANCER (2003)
A molecular signature of metastasis in primary solid tumors
S Ramaswamy et al.
NATURE GENETICS (2003)
Phase II Randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases
D Antonadou et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine
K Zulkowski et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2002)
Phase I/II clinical trial of concurrent radiochemotherapy in combination with topotecan for the treatment of brain metastases
K Grüschow et al.
EUROPEAN JOURNAL OF CANCER (2002)
Isolated brain metastases as the sole manifestation of a late relapse in breast cancer
MC Issa et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2002)
Current and future developments in the use of temozolomide for the treatment of brain tumours
R Stupp et al.
LANCET ONCOLOGY (2001)
Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer
MLH Wang et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2001)
Topotecan chemotherapy in patients with breast cancer and brain metastases:: Results of a pilot study
C Oberhoff et al.
ONKOLOGIE (2001)
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel
D Crivellari et al.
ANNALS OF ONCOLOGY (2001)
Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases
C Christodoulou et al.
ANNALS OF ONCOLOGY (2001)
A phase II trial of temozolomide for patients with recurrent or progressive brain metastases
LE Abrey et al.
JOURNAL OF NEURO-ONCOLOGY (2001)
The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid
WC Zamboni et al.
ANNALS OF ONCOLOGY (2001)
Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer
M Schwonzen et al.
ANTI-CANCER DRUGS (2000)